Psychosocial treatment of patients with schizophrenia and substance abuse disorders

Addictive Disorders and their Treatment

Volumn 5, Issue 2, 2006, Pages 53-66

  Tsuang, John ^a,b   Fong, Timothy W ^b   Lesser, Ira ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dual diagnosis; Psychosocial treatment; Schizophrenia; Substance abuse

Indexed keywords

METHADONE; PSYCHOTROPIC AGENT;

ABSTINENCE; ALCOHOL WITHDRAWAL; BEHAVIOR THERAPY; COGNITIVE THERAPY; COUNTER TRANSFERENCE; DRUG DEPENDENCE; DRUG DETOXIFICATION; HARM REDUCTION; HIGH RISK PATIENT; HUMAN; MENTAL PATIENT; PRIORITY JOURNAL; PROGNOSIS; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; SELF HELP; SOCIAL ADAPTATION; SUBSTANCE ABUSE; TRAINING; UTILIZATION REVIEW;

EID: 33745289382     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.adt.0000186367.15415.0d     Document Type: Review

References (98)

1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-2518.
2. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Nerv Ment Dis. 1987;175:641-652.
3. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: implications for treatment. J Consult Clin Psychol. 1992;60:845-856.
4. Soyka M, Albus M, Finelli A, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin Neurosci. 1993;242:362-372.
5. Green AI, Canuso CM, Brenner MJ, et al. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am. 2003;26:115-139.
6. Dickey B, Normand SL, Weiss RD, et al. Medical morbidity, mental illness, and substance use disorders. Psychiatr Serv. 2002;53:861-867.
7. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia: a prospective community study. J Nerv Ment Dis. 1989;177:408-414.
8. Owen RR, Fischer EP, Booth BM. Medication non-compliance and substance abuse among patients with schizophrenia. Psychiatr Serv. 1996;47:853-858.
9. Shaner A, Eckman TA, Roberts LJ, et al. Disability income, cocaine use, and repeated hospitalization among schizophrenic cocaine abusers - a government-sponsored revolving door? N Engl J Med. 1995;333:777-783.
10. Haywood TW, Kravitz HM, Grossman LS. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995;152:856-861.
11. Swofford CD, Kasckow JW, Scheller GG. Substance use: a powerful predictor of relapse in schizophrenia. Schizophr Res. 1996;20:145-151.
12. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35:S93-100.
13. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Bull. 2002;54:253-264.
14. Ries R, Mullen M, Cox G. Symptom severity and utilization of treatment resources among dually diagnosed inpatients. Hosp Community Psychiatry. 1994;45:562-568.
15. Dickey B, Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health. 1996;86:973-977.
16. Khantzian EJ. A self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985;142:1259-1264.
17. Green AI, Saloman MS, Brenner MJ, et al. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets-CNS & Neurol Disord. 2002;1:129-139.
18. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: a review of etiological theories. Addict Behav. 1998;23:717-734.
19. Potvin S, Stip E, Roy J. Schizophrenia and addiction: an evaluation of the self-medication hypothesis. Encephale. 2003;29:193-203.
20. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis: demographic characteristics, clinical features, and family history. Arch Gen Psychiatry. 1982;39:141-147.
21. Tsuang M, Lyons M, Tsuang J, et al. Relationship of Drug Abuse to Psychotic Symptoms. San Diego, CA: Symposium presentation at the American Psychiatric Association Annual Meeting; 1997.
22. Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull. 2000;26:105-118.
23. Bellack AS, Gearon JS. Substance abuse treatment for people with schizophrenia. Addict Behav. 1998;23:749-766.
24. Bellack AS, DiClemente C. Treating substance abuse among patients with schizophrenia. Psychiatr Serv. 1999;50:75-80.
25. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
26. Carey KB. Clinically useful assessments: substance use and comorbid psychiatric disorders. Behav Res Ther. 2002;40:1345-1361.
27. Negrete JC, Knapp WP, Douglas DE, et al. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med. 1986;16:515-520.
28. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996;40:1155-1163.
29. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273-279.
30. Allebeck P, Adamsson C, Engstrom A. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand. 1993;88:21-24.
31. Andresson S, Allebeck P, Engstrom A, et al. Cannabis and schizophrenia. Lancet. 1988;30:1000-1001.
32. Chambers RA, Self DW. Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia. Neuropsychopharmacology. 2002;27:889-905.
33. Shaner A, Roberts LJ, Eckman TA, et al. Sources of diagnostic uncertainty for chronically psychotic cocaine abusers. Psychiatr Serv. 1998;49:684-690.
34. Drake RE, Mercer-McFadden C, Mueser KT, et al. Review of integrated mental health and substance abuse treatment for patients with dual disorders. Schizophr Bull. 1998;24:589-608.
35. Minkoff K. Developing standards of care for individuals with co-occurring psychiatric and substance use disorders. Psychiatr Serv. 2001;52:597-599.
36. Roberts LJ, Shaner A, Eckman TA, et al. Effectively treating stimulant-abusing schizophrenics: mission impossible? New Dir Ment Health Serv. 1992Spring;53:55-65.
37. Tsuang J, Ho A, Eckman T, et al. Dual diagnosis treatment for patients with schizophrenia who abuse psychostimulants: rehab rounds. Psychiatr Serv. 1997;48:887-889.
38. Tsuang J, Fong T, Pi E. Pharmacological treatment of patients with schizophrenia and substance abuse disorders. Addict Disord Their Treatment. 2005;4:127-137.
39. Bustillo JR, Lauriello J, Keith SJ. Schizophrenia: improving outcome. Harv Rev Psychiatry. 1999;5:229-240.
40. Drake RE, Essock SE, Shaner A. Implementing dual diagnosis services for clients with severe mental illness. Psychiatr Serv. 2001;52:469-476.
41. Judd PH, Thomas N, Schwartz T, et al. A dual diagnosis demonstration project: treatment outcomes and cost analysis. J Psychoactive Drugs. 2003;35:181-192.
42. Klinkenberg WD, Calsyn RJ. Predictors of receipt of aftercare and recidivism among persons with severe mental illness: a review. Psychiatr Serv. 1996;47:487-497.
43. Penn DL, Mueser KT. Research update on the psychosocial treatment of schizophrenia. Am J Psychiatry. 1996;153:607-617.
44. Ho AP, Tsuang JW, Liberman RP, et al. Achieving effective treatment of patients with chronic psychotic illness and comorbid substance dependence. Am J Psychiatry. 1999;156:1765-1770.
45. Ziedonis DM, D'Avanzo K. Schizophrenia and Substance Abuse, Dual Diagnosis & Treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders. New York: Marcel & Dekker Inc.; 1998:427-465.
46. Brunette M. Psychological Intervention for Dual Diagnosis, Symposium on Dual Diagnosis: The Scope of the Problem. Atlanta, GA: Presented at the American Psychiatric Association Annual meeting; 2005.
47. DiClemente CC, Schlundt D, Gemmell L. Readiness and stages of change in addiction treatment, Distinguished Scholar Series. Am J Addict. 2004;13:103-119.
48. Torrey WC, Drake RE, Cohen M, et al. The challenge of implementing and sustaining integrated dual disorders treatment programs. Community Ment Health J. 2002;38:507-521.
49. Drake RE, Wallach MA, Alverson HS, et al. Psychosocial aspects of substance abuse by clients with severe mental illness. J Nerv Ment Dis. 2002;190:100-106.
50. Drake RE, Yovertich NA, Bebout RR, et al. Integrated treatment for dually diagnosed homeless adults. J Nerv Ment Dis. 1997;185:298-300.
51. Drake RE, Mueser KT. Managing comorbid schizophrenia and substance abuse. Curr Psychiatry Rep. 2001;3:418-422.
52. Havassy BE, Shopshire MS, Quigley LA. Effects of substance dependence on outcomes of patients in a randomized trial of two case management models. Psychiatr Serv. 2000;51:639-644.
53. Bradizaa CM, Stasiewicz PR. Integrating substance abuse treatment for the seriously mentally ill into psychiatric treatment. J Subst Abuse Treat. 1997;14:103-111.
54. Cuffel B, Shumway M, Chouljian T. A longitudinal study of substance use and community violence in the schizophrenic. J Nerv Ment Dis. 1994;182:704-708.
55. Moggi F, Crosby P, Moos RH, et al. Dual diagnosis patients in substance abuse treatment: relationship of general coping and substance-specific coping to 1-year outcomes. Addiction. 1999;94:1805-1816.
56. Mercer-McFadden C, Drake RE, Brown NB, et al. The community support program demonstration of services for young adults with severe mental illness and substance use disorders. Psychiatr Rehabil J. 1997;20:13-24.
57. Horvath AO, Greenberh LS. eds. The Working Alliance: Theory, Research, and Practice. New York: Wiley & Sons; 1994.
58. Jerrell JM, Ridgely MS. Impact of robustness of program implementation on outcomes of clients in dual diagnosis programs. Psychiatr Serv. 1999;50:109-112.
59. Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated outpatient treatment for substance-abusing schizophrenic patients. Am J Addict. 1995;4:33-42.
60. Clark RE, Teague GB, Ricketts SK, et al. Cost-effectiveness of assertive community treatment versus standard case management for persons with cooccurring severe mental illness and substance use disorders. Health Serv Res. 1998;33:1285-1308.
61. Lauriello J, Lenroot R, Bustillo JR. Maximizing the synergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatr Clin North Am. 2003;26:191-211.
62. Graeber DA, Moyers TB, Griffith G, et al. A pilot study comparing motivational and an educational intervention in patients with schizophrenia and alcohol use disorders. Community Ment Health J. 2003;39:189-202.
63. Miller WR, Yahne CE, Tonigan JS. Motivational interviewing in drug abuse services: a randomized trial. J Consult Clin Psychol. 2003;71:754-763.
64. Swanson AJ, Pantalon MV, Cohen KR. Motivational interviewing and treatment adherence among psychiatrically and dually diagnosed patients. J Nerv Ment Dis. 1999;187:630-635.
65. Martino S, Carroll K, Kostas D, et al. Dual diagnosis motivational interviewing for substance abusing patients with psychotic disorders. J Subst Abuse Treat. 2002;23:297-308.
66. Barrowclough C, Haddock G, Tarrier N, et al. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry. 2001;158:1706-1713.
67. Powell T, Kurtz L, Garvin C, et al. A model of AA. Utilization by persons with a dual diagnosis. Contemp Drug Probl. 1996;23:139-157.
68. Kurtz LF, Garvin CD, Hill EM, et al. Involvement in Alcoholics Anonymous by persons with dual disorders. Alcohol Treat Q. 1995;12:1-18.
69. Jordan LC, Davidson WS, Herman SE, et al. Involvement in 12-step programs among persons with dual diagnoses. Psychiatr Serv. 2002;53:894-896.
70. Magura S, Laudet A, Mahmood D, et al. Medication adherence and participation in self-help groups designed for dually diagnosed persons. Psychiatr Serv. 2002;53:310-316.
71. Magura S, Laudet A, Mahmood D, et al. Role of self-help processes in achieving abstinence among dually diagnosed persons. Addict Behav. 2003;28:399-413.
72. Noordsy DL, Drake RE, Teague GB, et al. Subjective experiences related to alcohol use among schizophrenics. J Nerv Ment Dis. 1991;179:410-414.
73. Laudet AB, Magura S, Cleland CM, et al. Predictors of retention in dual-focus self-help groups. Community Ment Health J. 2003;39:281-297.
74. Beck AT, Rector NA. Cognitive therapy of schizophrenia: a new therapy for the new millennium. Am J Psychother. 2000;54:291-300.
75. Beck AT, Rush AJ, Shaw BF, et al. Cognitive Therapy of Depression. New York: Guilford Press; 1979.
76. Beck AT. Cognitive Therapy and the Emotional Disorders. New York: International Universities Press; 1976.
77. Fairburn CG. Cognitive-behavioral treatment for bulimia. In: Garner DM, Garfinkel PE, eds. Handbook of Psychotherapy for Anorexia Nervosa and Bulimia. New York: Guilford Press; 1985.
78. Linehan MM. Cognitive Behavioral Treatment of Borderline Personality Disorder: The Dialectics of Effective Treatment. New York: Guilford Press; 1993.
79. Kohlenberg RJ, Tsai M. Functional Analytic Psychotherapy: Creating Intense Curative Therapeutic Relationships. New York: Plenum; 1991.
80. Tarrier N, Haddock G, Barrowclough C, et al. Are all psychological treatments for psychosis equal? The need for CBT in the treatment of psychosis and not for psychodynamic psychotherapy. Psychol Psychother. 2002;75:365-374.
81. Tarrier N, Kinney C, McCarthy E, et al. Two-year follow-up of cognitive-behavioral therapy and supportive counseling in the treatment of persistent symptoms in chronic schizophrenia. J Consult Clin Psychol. 2000;68:917-922.
82. Tarrier N, Sommerfield C, Pilgrim H, et al. Cognitive therapy or imaginal exposure in the treatment of post-traumatic stress disorder. Br J Psychiatry. 1999;175:571-575.
83. Carey KB. Substance use reduction in the context of outpatient psychiatric treatment: A collaborative, motivational, harm reduction approach. Community Ment Health J. 1996;32:291-306.
84. Sensky T, Turkington D, Kingdon D, et al. Cognitive-behavioral treatment for persistent symptoms in schizophrenia. Arch Gen Psychiatry. 2000;57:165-173.
85. Nigram R, Schottenfield R, Kosten TR. Treatment of dual diagnosis patients: a relapse prevention group approach. J Subst Abuse Treat. 1992;9:304-309.
86. Roder V, Brenner HD, Muller D, et al. Development of specific social skills training programmes for schizophrenia patients: results of a multicentre study. Acta Psychiatr Scand. 2002;105:363-371.
87. Roberts LJ, Shaner A, Eckmas T. Overcoming Addiction: Skills Training for People With Schizophrenia. New York: Norton Professional Books; 1999.
88. Shaner A, Eckman T, Roberts L, et al. Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia. Psychiatr Serv. 2003;54:1287-1289.
89. Higgins ST, Delaney DD, Budney AJ, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry. 1991;148:1218-1224.
90. Higgins ST, Budney AJ, Bickel WK, et al. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch Gen Psychiatry. 1994;51:568-576.
91. Higgins ST, Petry NM. Contingency management. Incentives for sobriety. Alcohol Res Health. 1999;23:122-127.
92. Petry N. A comprehensive guide to the application of contingency management procedures in clinical settings. Drug Alcohol Depend. 2000;58:9-25.
93. Shaner A, Roberts LJ, Eckman TA, et al. Monetary reinforcement of abstinence from cocaine among mentally ill patients with cocaine dependence. Psychiatr Serv. 1997;48:807-810.
94. Sigmon SC, Steingard S, Badger GJ, et al. Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: a feasibility study. Exp Clin Psychopharmacol. 2000;8:509-517.
95. Mueser KT, Fox L. A family intervention program for dual disorders. Community Ment Health J. 2002;38:253-270.
96. Rosenberg H, Phillips KT. Acceptability and availability of harm-reduction interventions for drug abuse in American substance abuse treatment agencies. Psychol Addict Behav. 2003;17:203-210.
97. Marlatt GA, Witkiewitz K. Harm reduction approaches to alcohol use: health promotion, prevention and treatment. Addict Behav. 2002;27:867-886.
98. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-1695.